HRT Over 65: Age Is Just a Number

Turning 65? Congratulations . . . No More Hormones for YOU! 

Nothing magical happens at midnight on the day a woman turns 65.

Her hormones don't know what year it is. Her symptoms don't reset at a birthday. Her cardiovascular system doesn't transform overnight. Her vaginal tissues don't suddenly enter a new phase that makes estradiol dangerous. And yet, in doctor's offices across the country, the same conversation plays out constantly: "You're 65 now. It's time to stop your hormones." Or worse: "You're 65 . . . I'm not going to start you on HRT."

No individual risk assessment. No discussion of the evidence. Just a number . . . and a door closed.

I want to challenge that directly. Because the idea that a specific age constitutes a bright line for HRT safety is not supported by the research. What the research actually supports, and what good clinical practice demands, is something harder, more time-consuming, and more expensive: genuine, individualized risk assessment for each woman, at every age.

Is that more work? Absolutely. Does it cost more time and money, for both the patient and the provider? Yes. Is it a lot more difficult than applying a simple rule? Without question. But it's the only way to actually know whether hormone therapy is right for a specific woman, and blanket denying care on the basis of a number is not good medicine. It is, at best, a shortcut. At worst, it leaves women suffering from treatable conditions for years or decades.

The Age Cutoff Has a History . . . But Not the Evidence You Think It Does

The age hesitation has a specific origin. It came from the Women's Health Initiative (WHI), a large randomized trial halted early in 2002 when it appeared to show increased risks of breast cancer, heart disease, and stroke in women on HRT. Doctors rewrote their protocols almost overnight. The FDA added a black box warning to all estrogen products. Women threw their prescriptions in the trash.

The problem, which took years to fully articulate, is that the WHI used oral conjugated equine estrogens combined with a synthetic progestin, and the women enrolled were on average 63 years old. Many were starting hormone therapy more than a decade after menopause onset, with underlying cardiovascular disease that had developed during untreated years. The study was not testing whether it was safe to continue estradiol in a healthy woman who had been on it since 52. It was testing something quite different.

For a full breakdown of what the black box warning actually said and why its claims were misleading, see my post on the FDA's black box warning. Notably: as of November 2025, the FDA removed cardiovascular disease, breast cancer, and probable dementia language from HRT boxed warnings entirely. The science had already moved on. The regulatory language finally caught up.

What never happened was a systematic reconsideration of the age-65 cutoff in clinical practice. The caution took root and stayed, even as the evidence evolved.

A Study of 10 Million Women Over 65 Said Something Different

A 2024 study published in Menopause (the journal of The Menopause Society) analyzed health records from more than 10 million Medicare women over the age of 65 and compared outcomes across 31 different HRT types, routes, and doses.

For women taking estradiol alone, the findings were striking:

• 19% reduction in all-cause mortality (HR 0.81; 95% CI 0.79–0.82)
• 16% reduction in breast cancer
• 13% reduction in lung cancer
• 12% reduction in colorectal cancer
• 11% reduction in heart attack
• Meaningful reductions in atrial fibrillation, congestive heart failure, and dementia

For combined estrogen-progestogen therapy: a 45% reduction in endometrial cancer and a 21% reduction in ovarian cancer.

The most telling number: 29 of the 31 HRT types studied showed either neutral or reduced mortality risk. Only two types were associated with increased risk.

The Menopause Society's official commentary on this study was pointed:

That is not a fringe position. That is The Menopause Society. And the data behind it is 10 million women.

But What About the Risks? Here's the Honest Picture.

I'm not going to tell you there are no considerations for older women on HRT. There are. And I want to be honest about that, because honesty is what makes individualized care possible.

Research does suggest that initiating hormone therapy for the first time at age 65 or older carries a different risk profile than continuing therapy that was started at 50 or 52. A large cohort study found that women who started HRT for the first time past 65, particularly those with underlying cardiovascular risk factors, had increased risk of certain events compared to women who started earlier. Timing is everything. The body's response to estrogen in a cardiovascular system that has been without it for 15 years is different from a body that has had it continuously.

But here is what I want to say clearly: elevated risk is not the same as disqualifying risk.

A woman past 65 who has some degree of cardiovascular risk is not automatically excluded from hormone optimization. There are formulations, routes, doses, and approaches specifically designed to minimize systemic exposure while still providing meaningful benefit. There are women with elevated risk profiles who, after genuine, thorough, individualized assessment, are excellent candidates for a carefully tailored regimen. The conversation is not binary. It is not "HRT or nothing." It is "what approach, if any, offers the best benefit-to-risk ratio for this specific woman."

That assessment requires a provider who takes time to understand her history, her current health status, her symptoms, her priorities, and the full range of available options. It is harder than applying a cutoff. It takes longer. It may require imaging, labs, specialist input. But it is the only honest approach to a question this complex.

What is not honest, and frankly not defensible, is the response too many women receive: "You're 65. No."

The Symptoms That Don't Care How Old You Are

Beyond the mortality data, there are practical reasons that make the age argument especially hard to accept.

Genitourinary syndrome of menopause (GSM) (vaginal dryness, painful intercourse, recurrent UTIs, urinary urgency) is a progressive condition that gets worse with time, not better. A woman at 68 who has had untreated GSM since 55 has accumulated more than a decade of tissue atrophy that no amount of age-based wisdom is going to reverse. Low-dose vaginal estradiol works directly on local tissue, is minimally absorbed into the bloodstream, and remains appropriate for most women regardless of age, including women who aren't candidates for systemic HRT. There is no credible evidence-based argument for withholding it based on a birthday.

Bone health. Estrogen is the primary protector of bone density in women. Stopping HRT removes that protection. A woman told at 65 to stop her estradiol because of "age" may spend the next 20 years at significantly elevated fracture risk, a risk that compounds over time and is one of the most serious causes of disability and mortality in older women. That is not a neutral outcome. It's a tradeoff that deserves to be named.

Cardiovascular health. The 10-million-woman study found an 11% reduction in heart attack risk and significant reductions in atrial fibrillation and congestive heart failure for estrogen users. The framing that estrogen is a cardiovascular risk for older women (the post-WHI framing) is increasingly hard to square with the accumulating evidence, particularly for women who have been on estradiol throughout their postmenopausal years.

Cognitive function. The data here is genuinely complex, and I won't overstate it. But the 10-million-woman study found a reduction in dementia risk for estrogen users. Multiple observational studies have found the same signal. This is not a reason to start HRT at 75 hoping to prevent Alzheimer's — timing is critical here, and starting late does not confer the same benefits — but it is highly relevant for women who started early and are being told to stop.

If you're past 65 and still having symptoms: You don't have to accept them as permanent, and you don't have to accept a blanket "no" as a medical opinion. The Menopause Solution is my 7-step course covering the full landscape of hormone optimization: what the evidence shows, how to talk to your doctor, and how to advocate for yourself when the default answer is a number rather than a conversation.

Start Step 1 Free →

What You Deserve From Your Provider

The age-65 cutoff is a proxy for a risk conversation that many providers don't feel equipped, or simply don't have time, to have. I understand that. Genuine individualized hormone assessment is demanding. It requires knowledge most doctors weren't taught in training, time most practices don't have built into appointments, and a willingness to sit with complexity rather than reach for a simple rule.

But the fact that individualized care is harder doesn't make the shortcut acceptable. And the shortcut ("you're 65, so no") is leaving real women with real symptoms living unnecessarily reduced lives.

What you deserve is a provider who asks: What are your symptoms? What is your cardiovascular health? What is your bone density? What does your personal history look like? What are your priorities? And given all of that . . . what does the full range of options look like for you?

If you're not getting that conversation, you may need a different provider. I maintain a referral list of trained, experienced hormone optimization specialists who take this approach: simplehormones.com/referral.

The Bottom Line

A birthday cake with "65" (or "60" or whatever arbitrary age) on it is a celebration. It is not a medical diagnosis. It is not a contraindication. It does not tell us anything, on its own, about whether hormone therapy is safe or appropriate for the woman blowing out the candles.

What tells us that is a careful, individualized assessment by a provider who knows the evidence, knows the options, and takes the time to know the patient.

That assessment is harder to deliver than a number. It is also the only kind of medicine that actually serves women.

A Note on This Post

I'm a pharmacist, not a physician. Nothing in this post is personal medical advice. This is educational content intended to help you have more informed conversations with your healthcare provider. Decisions about HRT (whether to continue, stop, or start) should be made with a knowledgeable provider who knows your full health history.